No Data
Eli Lilly, Novo Under Pressure as Biden Urges Lower Drug Prices
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer
Jefferies Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Raises Target Price to $53
Jefferies analyst Peter Welford maintains $GlaxoSmithKline(GSK.US)$ with a buy rating, and adjusts the target price from $28.48 to $53.According to TipRanks data, the analyst has a success rate of 52.
Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
A Delaware Superior Court judge rejected an appeal from GSK (GSK) and other drugmakers to overturn a ruling that cleared the way for over 70,000 lawsuits alleging that the heartburn drug Zantac causes
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Express News | GSK : Jefferies Raises Target Price to $53 From $52.5